Esophageal Clinical Trial
Endostar ® (recombinant human endostatin) continuous intravenous infusion combined with mPFC neoadjuvant treatment of esophageal cancer arm, Ⅱ single-center clinical trial.
1. Research purpose: Endostar (recombinant human endostatin) continuous intravenous infusion combined with chemotherapy for stage Ⅲ resectable or potentially resectable esophageal cancer efficacy and safety and to maintain the efficacy and safety. 2. The main objectives: R0 resection rate Secondary objectives: 1. pCR rate 2. 3-year disease-free survival 3. Security and complications 4. DFS, OS 5. Quality of Life 3.The number of research centers and research time: This study intends to preside and implemented by the Jiangsu Provincial People's Hospital, Professor Gu Yanhong. The trial is scheduled to start in September 2015, planned to stop in June 2016 into the group, one patient surgery follow-up to the last end, get the primary endpoint and safety, surgical complications secondary endpoint. This study will continue to follow-up the patient DFS, OS and other secondary end points. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT01842555 -
Photodynamic Therapy (PDT) Oncology Registry
|
||
| Completed |
NCT02591784 -
Nimotuzumab in Combination With Radiotherapy for Esophageal Cancer
|
Phase 2 | |
| Terminated |
NCT00618917 -
MnSOD (Esophageal Protectant) to Prevent Esophagitis During Radiation/Chemotherapy Treatment for Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
| Completed |
NCT02374255 -
Improving Goals of Care Discussion in Advanced Cancer Patients
|
N/A | |
| Terminated |
NCT01365130 -
Chemotherapy for Patients With Gastroesophageal Cancers Who Have Progressed After One Prior Chemo Regimen
|
Phase 2 |